161 related articles for article (PubMed ID: 37065272)
1. The patients` perspective on home-based infusion: A longitudinal observational study in the German healthcare setting for patients with lysosomal storage disorders treated with enzyme replacement therapy.
Heinrich R; Claus F; Schoenfelder T
Mol Genet Metab Rep; 2023 Jun; 35():100971. PubMed ID: 37065272
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
[TBL] [Abstract][Full Text] [Related]
3. Safety outcomes and patients' preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond.
Toscano A; Musumeci O; Sacchini M; Ravaglia S; Siciliano G; Fiumara A; Verrecchia E; Maione M; Gentile J; Fischetto R; Crescimanno G; Taurisano R; Sechi A; Gasperini S; Cianci V; Maggi L; Parini R; Lupica A; Scarpa M
Orphanet J Rare Dis; 2023 Oct; 18(1):338. PubMed ID: 37891668
[TBL] [Abstract][Full Text] [Related]
4. Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe.
Cox-Brinkman J; Timmermans RG; Wijburg FA; Donker WE; van de Ploeg AT; Aerts JM; Hollak CE
J Inherit Metab Dis; 2007 Nov; 30(6):984. PubMed ID: 17879143
[TBL] [Abstract][Full Text] [Related]
5. Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study.
Ditters IAM; van der Beek NAME; Brusse E; van der Ploeg AT; van den Hout JMP; Huidekoper HH
Orphanet J Rare Dis; 2023 May; 18(1):108. PubMed ID: 37158969
[TBL] [Abstract][Full Text] [Related]
6. Positive Impact of Home ERT for Mucopolysaccharidoses and Pompe Disease: The Lesson Learnt from the COVID-19 Pandemic.
Fiumara A; Lanzafame G; Sapuppo A; Arena A; Cirnigliaro L; Barone R
Healthcare (Basel); 2023 Apr; 11(8):. PubMed ID: 37108010
[TBL] [Abstract][Full Text] [Related]
7. [Lysosomal Storage Diseases: Challenges in Multiprofessional Patient Care with Enzyme Replacement Therapy].
Das AM; Lagler F; Beck M; Scarpa M; Lampe C
Klin Padiatr; 2017 May; 229(3):168-174. PubMed ID: 28464188
[No Abstract] [Full Text] [Related]
8. Fetal therapies and trials for lysosomal storage diseases: a survey of attitudes of parents and patients.
Schwab ME; Brown JEH; Lianoglou B; Jin C; Conroy PC; Gallagher RC; Harmatz P; MacKenzie TC
Orphanet J Rare Dis; 2022 Jan; 17(1):25. PubMed ID: 35093147
[TBL] [Abstract][Full Text] [Related]
9. Home therapy for lysosomal storage disorders.
Hughes DA; Mlilligan A; Mehta A
Br J Nurs; 2007 Dec 13-2008 Jan 9; 16(22):1384, 1386-9. PubMed ID: 18361386
[TBL] [Abstract][Full Text] [Related]
10. Treating lysosomal storage disorders: What have we learnt?
Lachmann RH
J Inherit Metab Dis; 2020 Jan; 43(1):125-132. PubMed ID: 31140601
[TBL] [Abstract][Full Text] [Related]
11. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide.
Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J
Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729
[TBL] [Abstract][Full Text] [Related]
12. Intravenous enzyme replacement therapy: hospital vs home.
Parini R; Pozzi K; Di Mauro S; Furlan F; Rigoldi M
Br J Nurs; 2010 Jul 22-Aug 11; 19(14):892-4, 896-8. PubMed ID: 20647981
[TBL] [Abstract][Full Text] [Related]
13. Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.
Rohrbach M; Clarke JT
Drugs; 2007; 67(18):2697-716. PubMed ID: 18062719
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy for lysosomal storage diseases.
Ohashi T
Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review.
Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A
Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638
[TBL] [Abstract][Full Text] [Related]
16. Impact of COVID-19 pandemic on healthcare delivery for lysosomal storage disorders at a tertiary care public hospital in Mumbai.
Muranjan M; Karande S; Rajoria S
J Postgrad Med; 2024; 70(1):23-28. PubMed ID: 38197333
[TBL] [Abstract][Full Text] [Related]
17. Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study.
Eskes ECB; Beishuizen CRL; Corazolla EM; van Middelaar T; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B
Orphanet J Rare Dis; 2022 Oct; 17(1):383. PubMed ID: 36271424
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal storage diseases: Stem cell-based cell- and gene-therapy.
Kim SU
Cell Transplant; 2014 May; ():. PubMed ID: 24853878
[TBL] [Abstract][Full Text] [Related]
19. Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group.
Concolino D; Amico L; Cappellini MD; Cassinerio E; Conti M; Donati MA; Falvo F; Fiumara A; Maccarone M; Manna R; Matucci A; Musumeci MB; Nicoletti A; Nisticò R; Papadia F; Parini R; Peluso D; Pensabene L; Pisani A; Pistone G; Rigoldi M; Romani I; Tenuta M; Torti G; Veroux M; Zachara E
Mol Genet Metab Rep; 2017 Sep; 12():85-91. PubMed ID: 28702361
[TBL] [Abstract][Full Text] [Related]
20. Cardiac involvement in Lysosomal Storage Diseases.
Sestito S; Parisi F; Tallarico V; Tarsitano F; Roppa K; Pensabene L; Chimenz R; Ceravolo G; Calabrò MP; De Sarro R; Moricca MT; Bonapace G; Concolino D
J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 2):107-119. SPECIAL ISSUE: FOCUS ON PEDIATRIC CARDIOLOGY. PubMed ID: 33000609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
